Recent studies have shown that combination therapies such as radiotherapy and chemotherapy, targeted therapies such as VEGF/VEGFR, cellular therapy, tumor vaccines, and oncolytic viruses can regulate PD-L1 in certain cancers [10, 12], making them ideal candidates for combination therapy with anti-PD-1/PD-L1. The gene discussed is KDR; the disease is neoplasm.